Floatz logo

Alemtuzumab

Severe Combined Immunodeficiency

Washington University School of Medicinemonoclonal_antibodyPhase 2/3Active
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
95/ 100

Competitive context

13 Active assets in the Severe Combined Immunodeficiency cohort.

Asset / SponsorPhaseRating
Fludarabine
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2/3BB
Nivestim
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2BB
Cyclophosphamide
St. Jude Children's Research Hospital
Phase 2/3BB
Busulfanum
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2/3BB
Thiotepa
St. Jude Children's Research Hospital
Phase 2BB

View all 30 →

Same molecule, other indications

Alemtuzumab is also rated in:

relapsing-remitting multiple sclerosisActive
BBB
Indicative · Phase 4
73 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmDormant
BB
Indicative · Phase 2
71 / 100
View asset →
chronic myeloid leukemiaActive
BB
Indicative · Phase 2/3
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →